What caused IGC's surprising Q2 2025 earnings surge?

IGC Pharma's Q2 2025 earnings did not show any surge. In fact, no financial data for IGC Pharma's Q2 2025 earnings was found. However, the company's recent expansions in its CALMA Phase 2 Alzheimer's trial, as reported in **News Articles** 2-4, 6-9, 11-13, might indicate active progress in their research and development pipeline, which could be a precursor to future growth and potential earnings surge if the trials are successful.

|code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code|
|---|---|---|---|---|---|---|
|IGC|IGC.A|IGC Pharma|2024 Q3|-38.55421686746988|204000|170|
|IGC|IGC.A|IGC Pharma|2024 Q4|77.71084337349397|295000|170|
|IGC|IGC.A|IGC Pharma|2025 Q1|-50.990990990990994|272000|170|
|IGC|IGC.A|IGC Pharma|2025 Q2|41.580756013745706|412000|170|